---
title: "Pre-market hot trades in US stocks: LanzaTech Global up 4.29% in pre-market; AXT down 3.21% in pre-market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283337911.md"
description: "LanzaTech Global rose 4.29% in pre-market; AXT Company fell 3.21% in pre-market; Theriva Biologics rose 91.99% in pre-market; Psyence Biomedical rose 84.21% in pre-market; Fitness Champs rose 65.71% in pre-market"
datetime: "2026-04-20T10:47:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283337911.md)
  - [en](https://longbridge.com/en/news/283337911.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283337911.md)
---

# Pre-market hot trades in US stocks: LanzaTech Global up 4.29% in pre-market; AXT down 3.21% in pre-market

**Pre-market Hot Trades in US Stocks**

LanzaTech Global is up 4.29% in pre-market trading. Based on recent key news:

1.  On April 17, LanzaTech Global released its latest financial report through the EDGAR system, showing significant progress in the company's technological innovations in sustainable energy. This news boosted market confidence and drove the stock price up.
    
2.  On April 16, LanzaTech Global again announced through the EDGAR system, emphasizing its breakthrough achievements in carbon capture and reuse technology, further enhancing investors' expectations for the company's future growth potential, leading to an increase in stock price. The renewable energy sector has performed strongly recently.
    

AXT is down 3.21% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

**Top Gainers in Pre-market US Stocks**

Theriva Biologics is up 91.99% in pre-market trading. Based on recent key news:

1.  On April 17, Theriva Biologics announced that it will present additional data from its VIRAGE 2B clinical trial at the AACR 2026 Annual Meeting. The trial involves the application of VCN-01 in metastatic pancreatic cancer, demonstrating improved overall survival and progression-free survival. This news drove the stock price up. Source: Reuters
    
2.  On April 17, the company plans to conduct a low-dose study to test whether more frequent and extended VCN-01 administration can further improve outcomes. This plan shows the company's confidence in its product, further stimulating market response. Source: GlobeNewswire
    
3.  On April 17, the clinical trial results from Theriva Biologics showed that patients using VCN-01 in combination with GnP performed better in overall survival and progression-free survival compared to those using GnP alone. This result enhanced investors' confidence in the company's product, driving the stock price up. Source: SEC Filing The biotechnology sector has performed strongly recently, with significant fund inflows.
    

Psyence Biomedical is up 84.21% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Fitness Champs is up 65.71% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation

### Related Stocks

- [LNZA.US](https://longbridge.com/en/quote/LNZA.US.md)
- [AXTI.US](https://longbridge.com/en/quote/AXTI.US.md)

## Related News & Research

- [If You Invested $1000 In AXT Stock 5 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/286283726.md)
- [LanzaTech Global Raises $20 Million in Registered Direct Offering, Eases PIPE Cash Threshold](https://longbridge.com/en/news/286761100.md)
- [AXT Turned the AI Data Center Boom Into an 8,436% 1-Year Return](https://longbridge.com/en/news/286650839.md)
- [AXT (AXTI) Is Down 7.8% After $632.5M Equity Raise To Boost Indium Phosphide Capacity](https://longbridge.com/en/news/284100852.md)
- [AXT  adjourns Annual Meeting of Stockholders to 4 June](https://longbridge.com/en/news/286800862.md)